The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

The following is a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks that hit 52-week highs on Feb. 21.)

  • Eli Lilly And Co LLY
  • Gossamer Bio Inc GOSS: IPO-ed on Feb. 8.
  • Immune Design Corp IMDZannounced a deal to be acquired by Merck & Co., Inc. MRK.
  • Intec Pharma Ltd NTEC
  • Omnicell, Inc. OMCL
  • PDL BioPharma Inc PDLI

Down In The Dumps

(Biotech stocks that hit 52-week lows on Feb. 21.)

  • Endologix, Inc. ELGX
  • Innovate Biopharmaceuticals Inc INNT
  • MOTIF BIO PLC/S ADR MTFB
  • Seelos Therapeutics Inc SEEL

Stock In Focus

Earnings

BioTelemetry Inc BEAT reported fourth-quarter revenues of $103.6 million, up 12.9 percent year-over-year, and adjusted earnings per share of 56 cents compared to the year-ago's 32 cents.

Analysts expected EPS of 43 cents per share on revenues of $102.84 million.

The stock fell 4.99 percent to $69.68 in after-hours trading.

bluebird bio Inc BLUE's fourth quarter revenues climbed from $4.2 million to $19.2 million. The company's net loss widened from $2.52 to $2.72. Analysts expected a wider loss of $2.86 per share on revenues of $8.12 million.

The stock rose 2.17 percent to $130 in after-hours trading.

TherapeuticsMD Inc TXMD said its fourth-quarter revenues increased from $4.1 million to $5.1 million. The net loss per share widened from 10 cents to 17 cents. The results matched analysts' expectation.

The stock rallied 3.93 percent to $5.29 in after-hours trading.

See also: Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial

BioMarin Pharmaceutical Inc. BMRN's 2018 fourth-quarter revenues of $353.2 million compared to $358.3 million in the year-ago period. The GAAP net loss narrowed from 30 cents per share to 3 cents per share.

On a non-GAAP basis, the company reversed to a loss of $10.8 million from a profit of $5.2 million.

For 2019, the company guided to revenue of $1.68 billion to $1.75 billion, while the consensus estimate calls for revenue of $1.73 billion.

The stock fell 5.98 percent to $83.50 in after-hours trading.

Moleculin Biotech Inc MBRX reported a loss of 46 cents per share for 2018 compared to 53 cents per share for 2017. Analysts had expected a loss of 47 cents per share.

The stock slipped 4.11 percent to $1.31 in after-hours trading.

On The Radar

Clinical Trial Results

  • Orchard Therapeutics PLC – ADR ORTX is due to present Phase 1/2 data for its OTL-101, being evaluated for adenosine deaminase severe combined immunodeficiency at 10:30 a.m. ET. 

Earnings

  • Momenta Pharmaceuticals, Inc. MNTA (before the market open)
  • Insmed Incorporated INSM

Related Link: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsTrading IdeasGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...